Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Long-term use of lithium and risk of colorectal adenocarcinoma: a nationwide case-control study.

Pottegård A, Ennis ZN, Hallas J, Jensen BL, Madsen K, Friis S.

Br J Cancer. 2016 Mar 1;114(5):571-5. doi: 10.1038/bjc.2016.10. Epub 2016 Feb 11.

2.

FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β.

Gao C, Chen G, Kuan SF, Zhang DH, Schlaepfer DD, Hu J.

Elife. 2015 Sep 3;4. doi: 10.7554/eLife.10072.

3.

Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders.

Beurel E.

Neuroimmunomodulation. 2014;21(2-3):140-4. doi: 10.1159/000356550. Epub 2014 Feb 14. Review.

4.

BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies.

Xu C, Aragam N, Li X, Villla EC, Wang L, Briones D, Petty L, Posada Y, Arana TB, Cruz G, Mao C, Camarillo C, Su BB, Escamilla MA, Wang K.

PLoS One. 2013;8(1):e51674. doi: 10.1371/journal.pone.0051674. Epub 2013 Jan 29.

5.

A review of the evidence for the canonical Wnt pathway in autism spectrum disorders.

Kalkman HO.

Mol Autism. 2012 Oct 19;3(1):10. doi: 10.1186/2040-2392-3-10.

6.

Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models.

Kramer T, Schmidt B, Lo Monte F.

Int J Alzheimers Dis. 2012;2012:381029. doi: 10.1155/2012/381029. Epub 2012 Jul 22.

7.

Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases.

Beurel E.

Front Mol Neurosci. 2011 Aug 31;4:18. doi: 10.3389/fnmol.2011.00018. eCollection 2011.

8.

Lithium suppresses astrogliogenesis by neural stem and progenitor cells by inhibiting STAT3 pathway independently of glycogen synthase kinase 3 beta.

Zhu Z, Kremer P, Tadmori I, Ren Y, Sun D, He X, Young W.

PLoS One. 2011;6(9):e23341. doi: 10.1371/journal.pone.0023341. Epub 2011 Sep 9.

9.

Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.

Martinez A, Gil C, Perez DI.

Int J Alzheimers Dis. 2011;2011:280502. doi: 10.4061/2011/280502. Epub 2011 Jun 30.

10.

Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, El-Deiry WS.

Cancer Res. 2011 Aug 1;71(15):5265-75. doi: 10.1158/0008-5472.CAN-11-1383. Epub 2011 Jun 6.

11.

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Chiu CT, Chuang DM.

Pharmacol Ther. 2010 Nov;128(2):281-304. doi: 10.1016/j.pharmthera.2010.07.006. Epub 2010 Aug 10. Review.

12.

Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression.

Camilli TC, Weeraratna AT.

Biochem Pharmacol. 2010 Sep 1;80(5):702-11. doi: 10.1016/j.bcp.2010.03.002. Epub 2010 Mar 6. Review.

13.

Abnormalities in brain structure and behavior in GSK-3alpha mutant mice.

Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberté C, Khan M, Okamoto K, Chambers JW, Fletcher PJ, MacAulay K, Doble BW, Henkelman M, Miyakawa T, Roder J, Woodgett JR.

Mol Brain. 2009 Nov 19;2:35. doi: 10.1186/1756-6606-2-35.

14.

Targeting protein kinases in central nervous system disorders.

Chico LK, Van Eldik LJ, Watterson DM.

Nat Rev Drug Discov. 2009 Nov;8(11):892-909. doi: 10.1038/nrd2999. Review.

15.

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Jope RS, Yuskaitis CJ, Beurel E.

Neurochem Res. 2007 Apr-May;32(4-5):577-95. Epub 2006 Aug 30. Review.

16.

The Wnt-dependent signaling pathways as target in oncology drug discovery.

Janssens N, Janicot M, Perera T.

Invest New Drugs. 2006 Jul;24(4):263-80. Review.

17.

Pharmacogenetics in mood disorder.

Nnadi CU, Goldberg JF, Malhotra AK.

Curr Opin Psychiatry. 2005 Jan;18(1):33-9.

18.

Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice.

Clément-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssière B, Belleville C, Estrera K, Warman ML, Baron R, Rawadi G.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17406-11. Epub 2005 Nov 17.

19.

GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid.

Jonathan Ryves W, Dalton EC, Harwood AJ, Williams RS.

Bipolar Disord. 2005 Jun;7(3):260-5.

Supplemental Content

Support Center